Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.

Matteo MonamiIlaria DicembriniEdoardo Mannucci

Published in: Acta diabetologica (2016)

Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.

Keyphrases

cardiovascular events
systematic review
coronary artery disease
cardiovascular disease
atrial fibrillation
heart failure
meta analyses
electronic health record
big data
randomized controlled trial
risk factors
case control
cerebral ischemia